# US 2026/0076980 A1 · Composition for the treatment of covid-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076980 A1
- Document ID: US20260076980A1
- Status: Published application
- Kind: A1
- Application number: 19/327,614
- Filed: 2025-09-12
- Published: 2026-03-19
- Earliest claimed: 2024-09-19
- Inventors: Albert Nguyen
- Web page: https://patentgrep.com/patent/US20260076980A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

## Claims

### Claim 1

A method for the treatment of COVID-19, the method comprising the steps of:
forming a first composition, comprising:
approximately 10 mg of dexamethasone; and
forming a second composition comprising approximately 48 mg to approximately 80 mg of the following:
approximately 48 mg to approximately 80 mg of triamcinolone acetonide;
sodium chloride;
benzyl alcohol;
carboxymethylcellulose sodium; and
polysorbate 80;
drawing the first composition into a 3 mL syringe;
drawing the second composition into the 3 mL syringe; and
injecting the combined composition from the syringe into a patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the second composition further comprises sodium hydroxide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second composition further comprises hydrochloric acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pH of the second composition is between approximately 5.0 and approximately 7.5.

### Claim 5 (depends on 1)

The method of claim 1, wherein an effective amount of the composition for the treatment of the patient having mild symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
48 mg of triamcinolone,
wherein the effective amount of the combined composition is administered once per day;
and once every subsequent two days until symptomatic resolution.

### Claim 6 (depends on 1)

The method of claim 1, wherein an effective amount of the composition for the treatment of the patient having moderate symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
60 mg of triamcinolone,
wherein the effective amount of the combined composition is administered once per day;
and once every subsequent two days until symptomatic resolution.

### Claim 7 (depends on 1)

The method of claim 1, wherein an effective amount of the composition for the treatment of the patient having severe symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
80 mg of triamcinolone,
wherein the effective amount of the combined composition is administered once per day;
and once every subsequent day until symptomatic resolution.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second compound is comprised of:
0.66% sodium chloride;
0.99% benzyl alcohol;
0.63% carboxymethylcellulose sodium; and
0.04% polysorbate 80.
